WEBSITE BSE:543960 NSE: CONCORDBIO Inc. Year: 1984 Industry: Pharmaceuticals & Drugs
Last updated: 15:50
Concord Biotech Ltd is a renowned biotechnology company with a global presence, specializing in the research, development, and production of high-quality biopharmaceuticals and specialty chemicals. Founded on a commitment to innovation and sustainability, Concord Biotech has established itself as a leader in the biotech industry. The company's core expertise lies in microbial fermentation and bioprocess technology, enabling them to create a diverse portfolio of products that range from antibiotics and enzymes to nutraceuticals. With state-of-t...Read More
Concord Biotech Ltd is a renowned biotechnology company with a global presence, specializing in the research, development, and production of high-quality biopharmaceuticals and specialty chemicals. Founded on a commitment to innovation and sustainability, Concord Biotech has established itself as a leader in the biotech industry. The company's core expertise lies in microbial fermentation and bioprocess technology, enabling them to create a diverse portfolio of products that range from antibiotics and enzymes to nutraceuticals. With state-of-the-art facilities and a talented team of scientists and engineers, Concord Biotech consistently delivers cutting-edge solutions for healthcare, agriculture, and industrial sectors. Dedicated to environmental responsibility, Concord Biotech places a strong emphasis on sustainable practices, ensuring their operations align with global eco-friendly standards. Their unwavering dedication to quality, research, and ethical business practices has earned them a stellar reputation in the biotech community, making them a trusted partner for clients worldwide. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹13214 Cr.
Stock P/E 35.6
P/B 7.2
Current Price ₹1263.1
Book Value ₹ 174.7
Face Value 1
52W High ₹2451.7
Dividend Yield 0.85%
52W Low ₹ 1225.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 |
| Other Income | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 |
| Total Income | 201 | 270 | 249 | 330 | 226 | 320 | 259 | 439 | 218 | 260 |
| Total Expenditure | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 159 |
| Operating Profit | 79 | 127 | 114 | 145 | 92 | 147 | 113 | 200 | 75 | 102 |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 83 |
| Provision for Tax | 17 | 29 | 26 | 34 | 20 | 35 | 25 | 43 | 15 | 23 |
| Profit After Tax | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 61 |
| Adjustments | 6 | -3 | 3 | -2 | 1 | -3 | 2 | -2 | 1 | 3 |
| Profit After Adjustments | 54 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 64 |
| Adjusted Earnings Per Share | 5.2 | 7.7 | 7.4 | 9.1 | 5.7 | 9.2 | 7.3 | 13.4 | 4.2 | 6.1 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 512 | 617 | 713 | 853 | 1017 | 1200 | 1125 |
| Other Income | 31 | 14 | 23 | 35 | 34 | 44 | 51 |
| Total Income | 544 | 631 | 736 | 888 | 1051 | 1245 | 1176 |
| Total Expenditure | 308 | 289 | 439 | 505 | 585 | 693 | 687 |
| Operating Profit | 236 | 342 | 297 | 384 | 466 | 551 | 490 |
| Interest | 1 | 1 | 6 | 10 | 3 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 64 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 213 | 313 | 238 | 322 | 413 | 495 | 424 |
| Provision for Tax | 45 | 78 | 63 | 82 | 104 | 123 | 106 |
| Profit After Tax | 169 | 235 | 175 | 240 | 308 | 372 | 320 |
| Adjustments | 0 | -0 | 0 | 0 | 0 | 0 | 4 |
| Profit After Adjustments | 169 | 235 | 175 | 240 | 308 | 372 | 324 |
| Adjusted Earnings Per Share | 16.2 | 22.4 | 16.7 | 22.9 | 29.5 | 35.5 | 31 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | 19% | 19% | 0% |
| Operating Profit CAGR | 18% | 23% | 18% | 0% |
| PAT CAGR | 21% | 29% | 17% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -40% | NA% | NA% | NA% |
| ROE Average | 22% | 21% | 21% | 22% |
| ROCE Average | 30% | 28% | 28% | 28% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | 770 | 999 | 1103 | 1290 | 1527 | 1813 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 36 | 56 | 31 | 6 | 0 | 0 |
| Other Non-Current Liabilities | 20 | 21 | 23 | 26 | 32 | 37 |
| Total Current Liabilities | 223 | 236 | 344 | 192 | 142 | 184 |
| Total Liabilities | 1049 | 1313 | 1502 | 1514 | 1701 | 2034 |
| Fixed Assets | 240 | 546 | 573 | 593 | 575 | 795 |
| Other Non-Current Assets | 271 | 159 | 296 | 193 | 229 | 104 |
| Total Current Assets | 539 | 607 | 633 | 728 | 896 | 1135 |
| Total Assets | 1049 | 1313 | 1502 | 1514 | 1701 | 2034 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 2 | 5 | 1 | 3 | 15 |
| Cash Flow from Operating Activities | 155 | 167 | 207 | 246 | 265 | 245 |
| Cash Flow from Investing Activities | -113 | -195 | -112 | -158 | -155 | -160 |
| Cash Flow from Financing Activities | -43 | 31 | -100 | -85 | -99 | -99 |
| Net Cash Inflow / Outflow | -1 | 3 | -4 | 3 | 12 | -14 |
| Closing Cash & Cash Equivalent | 2 | 5 | 1 | 3 | 15 | 1 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 16.15 | 22.45 | 16.72 | 22.95 | 29.45 | 35.52 |
| CEPS(Rs) | 18.18 | 25.08 | 21.5 | 28.11 | 34.57 | 40.72 |
| DPS(Rs) | 0.6 | 7.42 | 5.12 | 6.83 | 8.75 | 10.7 |
| Book NAV/Share(Rs) | 73.62 | 95.52 | 105.45 | 123.31 | 145.93 | 173.27 |
| Core EBITDA Margin(%) | 39.14 | 52.14 | 37.73 | 40.86 | 42.5 | 42.23 |
| EBIT Margin(%) | 41.07 | 49.89 | 33.56 | 38.89 | 40.88 | 41.3 |
| Pre Tax Margin(%) | 40.85 | 49.72 | 32.72 | 37.74 | 40.57 | 41.21 |
| PAT Margin (%) | 32.33 | 37.35 | 24.1 | 28.14 | 30.3 | 30.97 |
| Cash Profit Margin (%) | 36.4 | 41.73 | 30.99 | 34.47 | 35.57 | 35.5 |
| ROA(%) | 16.11 | 19.89 | 12.43 | 15.92 | 19.17 | 19.9 |
| ROE(%) | 21.94 | 26.55 | 16.64 | 20.06 | 21.88 | 22.26 |
| ROCE(%) | 26.23 | 32.96 | 21.66 | 26.7 | 29.13 | 29.62 |
| Receivable days | 128.17 | 104.76 | 102.99 | 108.22 | 111.87 | 132.49 |
| Inventory Days | 77.69 | 76.85 | 87.67 | 87.15 | 75.42 | 68.07 |
| Payable days | 200.1 | 192.42 | 144.1 | 179.16 | 149.88 | 123.94 |
| PER(x) | 0 | 0 | 0 | 0 | 51.68 | 47.19 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 10.43 | 9.67 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0.57 | 0.64 |
| EV/Net Sales(x) | 0.11 | 0.06 | -0.03 | -0 | 15.62 | 14.61 |
| EV/Core EBITDA(x) | 0.23 | 0.1 | -0.06 | -0 | 34.08 | 31.81 |
| Net Sales Growth(%) | 0 | 20.42 | 15.56 | 19.67 | 19.2 | 18.01 |
| EBIT Growth(%) | 0 | 46.17 | -22.35 | 36.18 | 25.3 | 19.21 |
| PAT Growth(%) | 0 | 39.02 | -25.53 | 37.25 | 28.33 | 20.62 |
| EPS Growth(%) | 0 | 38.99 | -25.51 | 37.25 | 28.33 | 20.62 |
| Debt/Equity(x) | 0.06 | 0.09 | 0.05 | 0.02 | 0 | 0 |
| Current Ratio(x) | 2.41 | 2.57 | 1.84 | 3.79 | 6.3 | 6.17 |
| Quick Ratio(x) | 1.91 | 1.92 | 1.27 | 2.69 | 4.84 | 4.87 |
| Interest Cover(x) | 183.92 | 299.68 | 39.72 | 33.85 | 130.57 | 475.76 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 |
| FII | 7.3 | 7 | 6.48 | 7.11 | 8.1 | 8.33 | 9.35 | 9.11 | 8.03 | 7.58 |
| DII | 8.12 | 8.4 | 8.41 | 10.35 | 9.82 | 9.59 | 9.14 | 8.85 | 9.54 | 9.57 |
| Public | 40.5 | 40.52 | 41.03 | 38.46 | 38 | 38 | 37.43 | 37.96 | 38.35 | 38.77 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 |
| FII | 0.76 | 0.73 | 0.68 | 0.74 | 0.85 | 0.87 | 0.98 | 0.95 | 0.84 | 0.79 |
| DII | 0.85 | 0.88 | 0.88 | 1.08 | 1.03 | 1 | 0.96 | 0.93 | 1 | 1 |
| Public | 4.24 | 4.24 | 4.29 | 4.02 | 3.98 | 3.97 | 3.92 | 3.97 | 4.01 | 4.06 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 | 10.46 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
